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Background: Rectal carcinoids are an uncommon entity comprising only 1%–2% of all rectal tumors. Rectal carcinoids
are frequently diagnosed during colonoscopy, but management after polypectomy is still controversial. The aims of this
study were to review the surgical procedures for rectal carcinoids and to compare the outcomes of patients after
different treatment modalities in a university hospital in Hong Kong.
Methods: All rectal carcinoids diagnosed between January 2003 and September 2012 were reviewed retrospectively,
including clinicopathological characteristics, their management, and surgical outcomes.
Results: There were 54 patients with a median age of 60 years, and 32 were males (59.3%). All patients underwent
colonoscopy, and the most had rectal bleeding (53.7%). Two patients were diagnosed incidentally in the surgical
specimens of rectal tissues. Eighteen patients were diagnosed to have rectal carcinoids after snaring polypectomy, and
no further intervention was required. Twenty-five patients had local resection either by means of transanal resection or
transanal endoscopic operation. Radical resection was performed in seven patients in which one had T3N1 disease and
the others did not have any lymph node metastasis.
In the median follow-up of 30 months (10–108 months), there was no recurrence in the “incidental” or post-polypectomy
group. However, two patients with transanal resection and two patients with radical resection developed hepatic
metastases after 13–24 months post-treatment. The 5-year overall survival was 100% in patients having snaring
polypectomy only, 83% for those with local resection, and 63% in patients who underwent radical surgery (p = 0.04).
Conclusions: Our data suggested that that local resection was an effective treatment for small rectal carcinoids and
generally brought about good oncological and surgical outcomes. For larger tumors, radical resection seemed to
provide acceptable oncological outcomes. Regular surveillance with colonoscopy and endorectal ultrasound is highly
recommended for high-risk patients for long-term management. By sharing our experience, we hope to provide more
evidence on the management on rectal carcinoids which, together with evidence from further studies, may guide us in
the long-term management of these patients in the future.Background
Carcinoid tumors, a type of neuroendocrine tumors,
comprise of a heterogeneous group of neoplasms arising
from enterochromaffin cells. These relatively uncommon
tumors have variable histological patterns and biologic
behaviors [1,2]. Rectum is the third most common site
of occurrence for carcinoids, with up to 13.7% of all car-
cinoids found at that site. On the other hand, carcinoids
only comprise of 1%–2% of all rectal tumors [3,4]. Both
the overall incidence of carcinoid tumors as well as the
proportion of rectal carcinoids in all rectal tumors has* Correspondence: rockson24@yahoo.com
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unless otherwise stated.been increasing drastically in recent years [3,4]. The ageing
population, increased rate of screening with colonoscopy,
and the increased awareness of the clinicians probably
account for this change in incidence [3]. Concerning
treatment, studies of different populations showed
that sizes of rectal carcinoid lesions are usually small
[2-4]. While larger lesions require major rectal resec-
tion, most can be treated with local excision either using
endoscopic means or via transanal route with good surgical
outcomes [5,6]. However, there is still no consensus on the
treatment strategy and surveillance of rectal cancer in gen-
eral yet [5,7,8].
The aims of this study were to review the surgical proce-
dures for rectal carcinoids and to compare the outcomes ofis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hospital in Hong Kong.
Methods
Patient inclusion
All patients who had treatment of rectal carcinoids at Queen
Mary Hospital between January 2003 and September 2012
were included in this study. All tumors were located within
15 cm from anal verge. Data on patients’ demographics, clin-
ical presentations, treatment modalities, recurrence, and sur-
vival were retrospectively reviewed and analyzed. The tumor
size was defined by the largest diameter of the tumor. Other
histopathological characteristics, such as resection margins,
mitotic rate, and immunostaining features, were searched for
and analyzed if available.
Treatment methods
Endoscopic treatment such as snaring polypectomy or
endoscopic mucosal resection resulting in adequately clear
margins was considered as curative treatment for small rec-
tal carcinoids (<10 mm). For larger rectal carcinoids
(>10 mm) or those with positive margin after polypectomy,
repeated resection was performed. Local excisional proce-
dures, either transanal resection or transanal endoscopic
operation (TEO), would be performed. Radical rectal resec-
tion (such as low anterior resection) was performed in pa-
tients with potentially aggressive carcinoids or concomitant
rectal adenocarcinoma.
All patients were followed up in outpatient clinic with
digital examinations performed at 2 to 4 weeks after op-
eration, and then at every 2–3-month intervals in the
first and second year. Follow-up appointments would
then be spaced out to yearly afterwards. We offer lifelong
follow-up assessment. Surveillance colonoscopy would beTable 1 Data on patients’ characteristics
Overall Siz
Age (median) 60 57
Male:female 32:22 26:
Presenting symptoms
Bleeding 28 (51.9%) 20
Tenesmus 6 (11.1%) 4 (7
Anal/rectal mass 7 (13.0%) 3 (5
Anal pain/discomfort 7 (13%) 3 (5
Carcinoid syndrome 1 (1.9%) 0 (0
Treatment modalities
Snaring polypectomy 18 (33.3%) 0 (0
Transanal resection 10 (18.5%) 4 (7
TEO 15 (27.5%) 3 (5
Radical resection 7 (13.0%) 3 (5
No treatment 4 (7.4) 2 (3arranged to look for any local recurrence or metachronous
colorectal malignancy in a 3-yearly interval. CT scan was
used only in 3- to 5-year intervals to look for distant me-
tastasis in patients who presented with poor prognostic
features.Statistical methods
Data were analyzed with PASW version 18. Continuous
variables were analyzed with t-test, whereas categorical
variables were compared with chi-square test. Kaplan
Meier survival curve was used for survival analysis, and
comparison was made with log-rank test. p values of less
than 0.05 were considered significant.Results
During the study period, there were 54 patients diag-
nosed to have rectal carcinoids and all were of Chinese
ethnicity. Thirty-two patients were males (59.3%), and
the median age was 61 among them all (range: 29 to
88 years). The most common presenting symptom was
rectal bleeding (53.7%). Only one patient had symptoms
of carcinoid syndrome with spurious diarrhea and flushing.
In large carcinoid tumors, (>10 mm), statistically significant
association was shown with symptoms of anal pain or dis-
comfort (p = 0.024) but not with bleeding (p = 0.349)
(Table 1).
In most patients, the diagnosis of carcinoid was made
by endoscopic examination and biopsy except for two
patients who were diagnosed to have rectal carcinoids
after surgical procedures for seemingly unrelated dis-
eases; one after hemorrhoidectomy and the other after
the transrectal prostate biopsy, with the specimens show-
ing the presence of rectal carcinoid.e <10 mm Size <10 mm p values
65 0.716
16 6:6 0.382
(37.0%) 8 (14.8%) 0.349
.4%) 2 (3.7%) 0.547
.6%) 4 (7.4%) 0.024
.6%) 4 (7.4%) 0.024
%) 1 (1.9%) 0.069
%) 18 (33.3%)
.4%) 6 (11.1%)
.6%) 12 (22.2%)
.6%) 4 (7.4%)
.7%) 2 (3.7%)
Wei et al. World Journal of Surgical Oncology  (2015) 13:31 Page 3 of 6Most gastrointestinal carcinoids can be recognized
during routine microscopic examination, but immuno-
histochemical staining is a useful aid. Chromogranin A,
a glycoprotein stored in secretory granules of neuroen-
docrine cells, was positive in 75.6% of the patients.
Synaptophysin, a neuron-specific enolase test, was found
positive in 97.9% of the patients.
The median size of the rectal carcinoids was 5 mm,
and it ranged from 1 to 60 mm. Seventeen patients with
small tumors were treated by snaring polypectomy
alone, and one patient had endoscopic mucosal resec-
tion. The median size of the tumor in this group of pa-
tients (group 1) was 4.5 mm (range: 1 to 8 mm). The
indications for further intervention after snaring poly-
pectomy included incomplete endoscopic removal or
positive resection margins (Table 2), and the 25 patients
belonging to this group (group 2) underwent either
transanal resection (18.5%) or TEO (27.8%). The median
tumor size in this group of patients was larger than that
in the previous group, being 6 mm (range: 1.5 to
25 mm). The third group (group 3) consisting of seven
patients (13.0%) who had radical resection for tumors of
larger size, concomitant rectal adenocarcinoma, or mar-
gin involvement (Table 2). Of these seven patients, one
had T3N1 disease and the other had T2 or less without
lymph node metastasis. Two other patients had meta-
static disease on presentation and therefore did not
undergo any surgical treatment.
During the median follow-up of 30 months (10 to
108 months), no local or systemic disease recurrence
was detected in the polypectomy alone group (group 1).
In the local resection group (group 2), three patients had
disease recurrence after transanal resection. None of the
patients who underwent TEO had disease recurrence.
One patient had local recurrence after 24 months and
was disease free for 35 months after another transanal
resection. The other two patients developed and subse-
quently died of systemic recurrence, one at 5 months
and the other at 13 months after initial operation. In the
radical resection group (group 3), one patient developed
local recurrence and two patients had liver metastases
within 1 year postoperatively. The other four patients
underwent low anterior resection for synchronous rectal
adenocarcinoma (7.0%), and all were disease free with
median follow-up of 2 years.Table 2 Indications for further intervention after snaring poly
Inadequate margins Large size Abnorm
Snaring polypectomy only N/A N/A N/A
Transanal resection 4 (7.4%) 4 (7.4%) 1 (1.9%)
TEO 8 (14.8%) 5 (9.3%) 0 (0%)
Radical resection 0 (0%) 3 (5.6%) 0 (0%)
N/A not applicable.Subsequently, in overall six patients died of disease
and their demographics were summarized in Table 3.
The most common site of distant metastases was liver
(100%), followed by bone (33%), lung (17%), and pan-
creas (17%). The overall 5-year disease-free survival was
87.0%. Concerning different treatment methods, the 5-
year overall survival was 100% in patients following snar-
ing polypectomy, 83% for those with local resection, and
63% for those with radical resection (p = 0.04) (Figure 1),
whereas the 5-year disease-free survival was 100% in pa-
tients following snaring polypectomy, 73% for those with
local resection, and 51% for those with radical resection
(p = 0.07) (Figure 2). Considering association of tumor
size and prognosis, patients with tumor size of more
than 10 mm showed significantly worse 5-year disease-
free survival than those with less than 10 mm (37% vs
97.1%) (p = 0.001) (Figure 3).
Discussion
Rectal carcinoids are usually small at the initial presenta-
tion, and most studies reported a median size of 6 mm,
compared with a median size of 1–3 cm in colonic carci-
noids [5,9]. Similarly, the median size of the rectal carci-
noids in this study was 5 mm, and it ranged from 1 to
60 mm. Patients with rectal carcinoids usually present
with local symptoms. Many were diagnosed incidentally
during endoscopy (31.5%). Carcinoid syndrome is associated
with excessive secretion of serotonin, tachykinins, prostaglan-
dins, catecholamines, and histamine. 5-Hydroxyindoleacetic
acid (5-HIAA), their metabolite, was excreted in the urine,
allowing it to be used as a diagnostic and postoperative sur-
veillance marker. However, as hindgut carcinoid rarely se-
cretes serotonin, carcinoid syndrome is uncommon and
urinary 5-HIAA is seldom elevated [10]. This explains why
in our study, only one patient had carcinoid syndrome and
elevated urinary 5-HIAA (1/54). Immunohistochemical
staining as an aid for the diagnosis of rectal carcinoid had
also been explored in our study. Chromogranin A had a
much lower sensitivity of 75.6% in our study, compared with
97.9% for synaptophysin. Eriksson et al. suggested using
plasma chromogranin A for monitoring of disease progres-
sion in midgut neuroendocrine tumors (NETs) especially in
patients with metastatic disease, but not in hindgut NETs,
since there was limited evidence to suggest similar
applicability [11].pectomy
al imaging Submuscosal lesion Concomitant tumor Total
N/A N/A 18 (33.3%)
1 (1.9%) 0 (0%) 10 (18.5%)
2 (3.7%) 0 (0%) 15 (27.8%)
0 (0%) 4 (7.4%) 7 (13.0%)
Table 3 Data on patients’ demographics who developed distant metastases
Age Sex Size (mm) Treatment Site of metastasis Survival (months)
48 M 34 LAR Liver 22
53 M 25 Not treated Liver 8
64 M 60 Not treated Liver, bone 1
65 F 15 Transanal excision, chemotherapy after metastasis Liver, bone 24
74 M 25 Transanal excision Liver, pancreas 13
77 F 15 LAR Liver 5
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tion is an adequate treatment for most rectal carcinoids
with small size [5,6]. In our study, one third of patients
were diagnosed incidentally after endoscopic polypect-
omy, and no further intervention was needed. None sub-
sequently developed local recurrence during follow-up.
For larger tumors or those with margin involvement,
local excision (either transanal excision or TEO) was
performed. The latter approach could be employed for
upper rectal lesions with better visualization and ad-
equate margin with low morbidity [8]. However, both
surgical approaches cannot remove potentially involved
regional lymph nodes, which have been reported to have
an incidence of up to 8.3% [7]. In our series, these pa-
tients had good outcome with a 5-year overall survival
of 83% and 5-year disease-free survival of 72%, reflecting
the adequacy of local treatment. From the limited num-
ber of patients who underwent local excision, we found
that the use of TEO could achieve complete excision
with clear margins. No patients had recurrence after theFigure 1 Patients’ overall survival following snaring polypectomy, witprocedure. For large rectal carcinoids which required
radical resection, the 5-year overall survival rate was
63% and disease-free survival was 50%. Radical resection
for this group of patients was necessary due to larger
tumor size and the possibility of loco-regional lymph
node metastasis [7]. The study showed that the 5-year
overall survival was 100% in patients following snaring
polypectomy, 83% for those with local resection, and
63% for those with radical resection, which is compar-
able with the reported 5-year survival rate of about 88%
for all tumor stages [5,12,13].
Size is an important and known prognostic factor for
carcinoids, and those less than 10 mm are even consid-
ered benign [5,6,12,13]. Other important factors include
the depth of invasion, lymphovascular invasion (LVI),
and the number of mitotic figures [12,14-16]. Larger pri-
mary tumors in our study (>10 mm in size) were associ-
ated with a worse prognosis with 5-year survival of only
37%, and this was consistent with previous reports
[2,5,12]. Our metastatic rate was 9.3%, consistenth local resection, and with radical resection (p = 0.04).
Figure 2 Patients’ disease-free survival following snaring polypectomy, with local resection, and with radical resection (p = 0.07).
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[12,17,18]. Mostly rectal carcinoids are localized with
a low propensity of metastasis at the time of diagnosis,
with the rate of metastasis ranging from 1.7% to 3.4%
[6,19]. In the case of large tumors or perceived advanced
disease, further imaging such as computed tomography,
PET scans, or endorectal ultrasound is indicated [5,7].Figure 3 Patients with tumor size of more than 10 mm showed signifSynchronous non-neuroendocrine tumors were re-
ported in the literatures with incidences of 25% to 46%
[20,21]. Interestingly, most synchronous tumors were
observed in the gastrointestinal tract, whereas metachro-
nous tumors were more often observed outside the gastro-
intestinal tract [13,20]. As the presence of a metachronous
malignancy was associated with more aggressive behavioricantly worse 5-year disease-free survival.
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cases [22]. In our study, four patients had synchronous car-
cinoma of rectum, and none of them developed metachro-
nous tumors or recurrence.
Few clear recommendations are available on post-
treatment surveillance of NETs [5,7,23]. In our center, the
patients were followed up 2–3 monthly in the first two
postoperative years, followed by lifelong annual assessment
afterwards. Though surveillance endoscopy in this context
had not been widely documented in medical literature,
regular colonoscopy would be considered every 3–5 years
with an aim to rule out local recurrence and metachronous
colorectal malignancy [7,23]. Although most local recur-
rences could be detected by digital examination and col-
onoscopy in our patients, some smaller submucosal
recurrence could still be missed. Endorectal ultrasound in
this case can play a role in identifying small submucosal
recurrence, and it is recommended as a surveillance tool
for monitoring local disease recurrence [7,23]. For those
stage II/III diseases, surveillance with computed tomog-
raphy would be essential to look for any distant metasta-
ses, particularly liver metastases, as we have been offering
to our patients. As distant metastases may occur years
after the initial treatment, long-term surveillance beyond
5 years had been suggested in patients with high-risk fac-
tors such as large size and advanced tumor staging with
lymph node metastasis [23]. Chromogranin A is not com-
monly elevated in this group of patients, thus limiting
their utilization [11].
Conclusions
Our data suggested that that local resection was an effective
treatment for small rectal carcinoids and generally brought
about good oncological and surgical outcomes. For larger
tumors, radical resection seemed to provide acceptable
oncological outcomes. Regular surveillance with colonoscopy
and endorectal ultrasound is highly recommended for
high-risk patients for long-term management. By sharing
our experience, we hope to provide more evidence on the
management on rectal carcinoids which, together with
evidence from further studies, may guide us in the
long-term management of these patients in the future.
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